If symptoms resolve and CK levels ≤ return to normal, then consideration should be given to re-introducing Crestor or an alternative HMG- CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted.